UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept ...

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

It also improves patients' exercise capacity and reduces pulmonary vascular resistance. These outcomes suggest the potential to extend patients' average life expectancy by over ten years when combined ...

Chronic respiratory infections, like bronchitis or pneumonia, can make life difficult, especially for people with conditions ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.

Results Quantitative questionnaire results revealed an adherence rate of 52.3%. Marital status, residence location, exercise habit, smoking index and pulmonary function were identified as independent ...

Patients with pulmonary arterial hypertension and cardiovascular comorbidities may benefit from the use of inhaled or oral ...

No difference was observed between center-based pulmonary rehabilitation vs home-based telerehabilitation in the proportion of patients showing improvement in functional exercise capacity, ...